A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Phase 3
Active, not recruiting
NCT05723835
| Condition | SGA, Turner Syndrome, Noonan Syndrome, ISS |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Novo Nordisk A/S |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 47 participants |
|---|
| Interventions | Somapacitan |
|---|
| Start date | Feb 1, 2023 |
|---|
| Completion date | Jun 7, 2024 |
|---|
| Results posted | Nov 21, 2025 |
|---|
Summary
The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nurse will show how to inject somapacitan, so that the participant knows how to do it at home.
Number of Adverse Events (AEs) Reported in Children Born Small for Gestational Age- Weeks 0 to 26
From baseline (Week 0) to Week 26 · Events
| SGA_somapacitan (GH Treatment Naïve) | 4 Events |
|---|
| SGA_somapacitan (Previously Treated With GH) | 10 Events |
|---|
Number of Adverse Events Reported for Turner Syndrome (TS)- Weeks 0 to 26
From baseline (Week 0) to Week 26 · Events
| TS_somapacitan (GH Treatment Naïve) | 4 Events |
|---|
| TS_somapacitan (Previously Treated With GH) | 18 Events |
|---|
Number of Adverse Events Reported for Noonan Syndrome- Weeks 0 to 26
From baseline (Week 0) to Week 26 · Events
| NS_somapacitan (GH Treatment Naïve) | 13 Events |
|---|
| NS_somapacitan (Previously Treated With GH) | 11 Events |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.